Department of Medical Biotechnology, School of Advanced Technologies in Medicine, Tehran University of Medical Sciences, Tehran, Iran; Department of Medical Biotechnology, School of Medicine, Lorestan University of Medical Sciences, Lorestan, Iran.
Department of Medical Biotechnology, School of Advanced Technologies in Medicine, Tehran University of Medical Sciences, Tehran, Iran; Tehran University of Medical Sciences International Campus (TUMS-IC), Tehran, Iran.
Biomed Pharmacother. 2017 Feb;86:221-231. doi: 10.1016/j.biopha.2016.12.021. Epub 2016 Dec 19.
Cancer is the second cause of death in 2015, and it has been estimated to surpass heart diseases as the leading cause of death in the next few years. Several mechanisms are involved in cancer pathogenesis. Studies have indicated that proteases are also implicated in tumor growth and progression which is highly dependent on nutrient and oxygen supply. On the other hand, protease inhibitors could be considered as a potent strategy in cancer therapy. On the basis of the type of the key amino acid in the active site of the protease and the mechanism of peptide bond cleavage, proteases can be classified into six groups: cysteine, serine, threonine, glutamic acid, aspartate proteases, as well as matrix metalloproteases. In this review, we focus on the role of different types of proteases and protease inhibitors in cancer pathogenesis.
癌症是 2015 年的第二大死亡原因,据估计,在未来几年内,癌症将超过心脏病成为主要死因。癌症的发病机制涉及多种机制。研究表明,蛋白酶也与肿瘤的生长和进展有关,而肿瘤的生长和进展高度依赖于营养和氧气的供应。另一方面,蛋白酶抑制剂可以被认为是癌症治疗的一种有效策略。根据蛋白酶活性部位关键氨基酸的类型和肽键裂解的机制,蛋白酶可以分为六类:半胱氨酸蛋白酶、丝氨酸蛋白酶、苏氨酸蛋白酶、谷氨酸蛋白酶、天冬氨酸蛋白酶以及基质金属蛋白酶。在这篇综述中,我们重点讨论了不同类型的蛋白酶和蛋白酶抑制剂在癌症发病机制中的作用。